SynthesisBreast cancer research : BCR2025

Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.

Lis Victoria Ravani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.